Vigilante

You Might Also Like: Takin' Care of Lady Business®


Listen Later

Introducing S2Ep104: How Dr. Piraye Beim & Celmatix Are Preserving Women's Health One Ovary at a Time from Takin' Care of Lady Business®.

Follow the show: Takin' Care of Lady Business®

In this episode, Jennifer Justice shines a light on the transformative efforts in women's health led by Dr. Piraye Yurttas Beim, the CEO of Celmatix. Dr. Beim's work exemplifies the uphill battle female founders often endure in the healthcare sector, a field historically sluggish to innovate expressly for women's needs. Despite pervasive sexism within the venture capital landscape, where a meager 2% of funds are allocated to female-led startups, Dr. Beim has secured over $150MM in funding. Celmatix stands out for its dedication to developing medications targeted at conditions uniquely affecting women, a neglected area in pharmaceutical research for almost a century. This pioneering work is not just advancing health solutions but is also making a substantial impact on society at large.
Key Takeaways
Learn about Celmatix's oral FSH program, a potential game changer in fertility treatment, shifting from invasive injections to a simple daily pill.
Discover what Celmatix is doing to revolutionize fertility treatments and extend ovarian function to make menopause a choice rather than an inevitability.
Understand the burdens of current infertility treatments on women and how Celmatix is developing less invasive options, like an oral fertility drug.
Uncover the broader implications of women's health on society and the economy and the importance of addressing these issues for global progress.
Hear Dr. Beim’s personal experiences with sexism and the substantial barriers she faced in a male-dominated VC world despite successfully raising over $150MM.
Resources
Connect with Dr. Beim: https://www.linkedin.com/in/pirayebeim/
Follow Dr. Beim: https://www.instagram.com/boss_ovary/, https://twitter.com/pirayebeim
Learn about Celmatix: https://www.celmatix.com/
Follow Celmatix:  https://www.instagram.com/celmatix/, https://twitter.com/celmatix
 About Our Guest 
Dr. Piraye Yurttas Beim, PhD, is the founder and CEO of Celmatix, a biotech transforming women’s lives through better medications. Dr. Beim is recognized for pioneering the emerging field of "ovarian health," a term she coined in 2020 to underscore that the ovary is not just an egg factory, but a vital female organ. For over 20 years, she has been leading the innovation of cutting-edge health solutions that are purpose built for women's bodies. Her life’s work and mission will culminate in a future in which the timing of menopause is a choice that every woman gets to make for herself. Dr. Beim completed her PhD work at Cornell (Weill)/Memorial Sloan Kettering Cancer Center in NYC and her postdoctoral research at the University of Cambridge, first focusing on women’s health oncology and then shifting to women’s reproductive health. When she moved into reproductive health, she was inspired by the precision medicine revolution in oncology and was early in seeing how the same playbook of genomics guided discovery and medicine could be a gamechanger for women outside of cancer. Given funding disparities in women’s health research, she transitioned to entrepreneurship and founded Celmatix in 2009, where her research teams have pioneered breakthroughs in decoding the genomic drivers of ovarian function and health through a multi-omic data initiative that has yielded unprecedented insight into the key molecular drivers of ovarian function and reproductive health conditions. Under her leadership, Celmatix is progressing 5 innovative drug programs, including an AMH agonist program aimed at optimizing and extending ovarian function and an oral fertility drug program to eliminate needles from IVF and egg freezing. She is a member of the Aspen Global Leadership Network, was named to Crain’s 40 Under 40 and its Notable Women in Tech, twice to Goldman Sachs's Most Intriguing Entrepreneurs list, Top 15 founders disrupting their industries by Fortune, and Rock Health's Disruptive Founder of the Year. Celmatix was named one of the most innovative companies in the world by Fast Company.
Learn more about your ad choices. Visit megaphone.fm/adchoices

DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to [email protected].

...more
View all episodesView all episodes
Download on the App Store

VigilanteBy PodcastOne

  • 4.1
  • 4.1
  • 4.1
  • 4.1
  • 4.1

4.1

1,380 ratings


More shows like Vigilante

View all
Sword and Scale by Sword and Scale

Sword and Scale

62,425 Listeners

Generation Why: True Crime by Wondery

Generation Why: True Crime

17,274 Listeners

PRETEND by True Story Media

PRETEND

2,476 Listeners

Swindled by A Concerned Citizen

Swindled

9,808 Listeners

Something Was Wrong by Broken Cycle Media

Something Was Wrong

25,552 Listeners

Culpable by Tenderfoot TV & Audacy

Culpable

22,576 Listeners

The Binge Cases: Where is Daniel Morcombe? by Sony Music Entertainment

The Binge Cases: Where is Daniel Morcombe?

4,205 Listeners

Unraveled by ID

Unraveled

10,535 Listeners

The Opportunist by PodcastOne

The Opportunist

10,348 Listeners

Queen of the Con by iHeartPodcasts and AYR Media

Queen of the Con

3,649 Listeners

What Happened to Talina Zar by iHeartPodcasts

What Happened to Talina Zar

1,765 Listeners

Scamfluencers by Wondery

Scamfluencers

7,337 Listeners

Betrayal: Weekly by iHeartPodcasts and Glass Podcasts

Betrayal: Weekly

7,855 Listeners

Good Cult by Good Cult

Good Cult

1,483 Listeners

Lost In Panama by PodcastOne

Lost In Panama

1,180 Listeners

Blink | Jake Haendel's Story by Sony Music, Corinne Vien, Jacob Haendel

Blink | Jake Haendel's Story

6,978 Listeners

Conspiracy Theories, Cults, & Crimes by Crime House

Conspiracy Theories, Cults, & Crimes

308 Listeners